SCHEMBL4773203

SCHEMBL4773203

NC(=O)CCS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(-c2cnco2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
NOTUM Q6P988 1/20 0.35
PARP1 P09874 1/20 0.35
GAA P10253 1/20 0.34
HDAC6 Q9UBN7 2/20 0.34
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 2/20 0.34
PKM P14618 2/20 0.34
CCR9 P51686 3/20 0.33
POLB P06746 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776753 0.89 GAA (0.35) KMT2AMEN1CYP3A4CYP2D6PSEN1
SCHEMBL4776219 0.88 GAA (0.36) KMT2AMEN1CYP3A4CYP2D6PSEN1
SCHEMBL4770724 0.87 GPR119 (0.36) KMT2AMEN1CYP3A4CYP2D6PSEN1
SCHEMBL4796737 0.87 CYP3A4 (0.36) KMT2AMEN1CYP3A4CYP2D6PSEN1
SCHEMBL4795759 0.87 CYP3A4 (0.36) KMT2AMEN1CYP3A4CYP2D6PSEN1
SCHEMBL4767799 0.84 GAA (0.34) KMT2AMEN1CYP3A4CYP2D6PSEN1
SCHEMBL4790813 0.83 CYP3A4 (0.35) KMT2AMEN1CYP3A4CYP2D6PSEN1
SCHEMBL4775343 0.83 GAA (0.37) KMT2AMEN1CYP3A4CYP2D6PSEN1
SCHEMBL4777511 0.83 GAA (0.43) KMT2AMEN1CYP3A4CYP2D6PSEN1
SCHEMBL4793479 0.83 CYP3A4 (0.37) KMT2AMEN1CYP3A4CYP2D6PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 KMT2A 1501/4885MEN1 1302/4885CYP3A4 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.